CHE CHEMED CORP
Services-Home Health Care Services · NYSE · SEC CIK 19584 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.2%
TTM net income YoY1.3%
TTM EPS YoY10.5%
Revenue 3-yr CAGR6.1%
Net income 3-yr CAGR4.9%
Margins
Gross margin33.6%
Operating margin13.9%
Net margin10.6%
FCF margin11.1%
EBITDA margin16.3%
Returns
ROE29.1%
ROA16.9%
ROIC (approx.)27.4%
Asset turnover1.59x
Leverage & solvency
Liabilities / assets49.9%
Debt / equity0.27x
Current ratio1.11x
Interest coverage75.39x
Cash quality & payout
Operating cash flow / net income1.29x
Accruals ratio-4.8%
Payout ratio11.9%
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.53B | $2.43B | $2.26B | $2.13B | $2.14B |
| Cost of revenue | $1.71B | $1.58B | $1.47B | $1.37B | $1.37B |
| Gross profit | $823.18M | $854.35M | $798.82M | $765.09M | $769.80M |
| SG&A expense | $417.19M | $424.36M | $395.12M | $358.73M | $366.73M |
| Operating income | $338.25M | $366.49M | $340.57M | $343.50M | $343.04M |
| Interest expense | $1.75M | $1.78M | $3.11M | $4.58M | $1.87M |
| Pretax income | $355.78M | $399.46M | $350.37M | $329.68M | $350.31M |
| Income tax | $90.54M | $97.47M | $77.86M | $80.06M | $81.76M |
| Net income | $265.24M | $302.00M | $272.51M | $249.62M | $268.55M |
| EBITDA | $403.09M | $429.54M | $401.43M | $402.67M | $402.09M |
| EPS (basic) | 18.42 | 20.10 | 18.11 | 16.72 | 17.14 |
| EPS (diluted) | 18.34 | 19.89 | 17.93 | 16.53 | 16.85 |
| Dividends declared per share | 2.20 | 1.80 | 1.56 | 1.48 | 1.40 |
| Weighted avg. shares (diluted) | 14.46M | 15.19M | 15.20M | 15.10M | 15.94M |
| Balance sheet | |||||
| Cash & equivalents | $74.52M | $178.35M | $263.96M | $74.13M | $32.90M |
| Receivables | $182.57M | $171.16M | $181.51M | $139.41M | $137.22M |
| Inventory | $7.54M | $8.19M | $12.00M | $10.27M | $10.11M |
| Current assets | $302.62M | $394.75M | $500.84M | $272.61M | $230.29M |
| PP&E, net | $205.66M | $200.84M | $203.84M | $199.71M | $193.68M |
| Goodwill | $667.00M | $666.74M | $585.02M | $581.29M | $578.59M |
| Intangibles | $82.76M | $92.21M | $90.26M | $99.73M | $108.10M |
| Total assets | $1.54B | $1.67B | $1.67B | $1.44B | $1.34B |
| Current liabilities | $287.13M | $285.69M | $312.05M | $297.20M | $302.40M |
| Short-term debt | — | — | — | $5.00M | — |
| Long-term debt | — | — | — | $92.50M | $185.00M |
| Total debt | — | — | — | $97.50M | $185.00M |
| Total liabilities | $558.78M | $549.58M | $560.22M | $643.30M | $719.45M |
| Shareholders' equity | $979.40M | $1.12B | $1.11B | $798.72M | $623.27M |
| Net debt | — | — | — | $23.37M | $152.10M |
| Cash flow statement | |||||
| Operating cash flow | $388.27M | $417.50M | $330.30M | $309.89M | $308.60M |
| Capital expenditure | $62.80M | $49.53M | $56.85M | $57.33M | $58.67M |
| Free cash flow | $325.48M | $367.97M | $273.44M | $252.56M | $249.92M |
| Investing cash flow | -$59.34M | -$143.91M | -$60.64M | -$59.40M | -$57.76M |
| Financing cash flow | -$432.77M | -$359.19M | -$79.83M | -$209.25M | -$380.62M |
| Depreciation & amortization | $64.84M | $63.05M | $60.87M | $59.17M | $59.05M |
| Stock-based compensation | $38.68M | $52.11M | $40.79M | $33.61M | $31.42M |
| Dividends paid | $31.70M | $27.09M | $23.50M | $22.02M | $22.02M |
| Share buybacks | $431.50M | $361.39M | $67.70M | $114.52M | $576.04M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.